EU Panel Gives Thumbs-Up on First Ebola Vaccine EU Panel Gives Thumbs-Up on First Ebola Vaccine
The V920 Ebola Zaire vaccine (Ervebo, Merck) protects against Ebola virus disease caused by Zaire Ebola virus in at-risk adults aged 18 years or older.International Approvals
Merck's Ervebo gets its first regulatory greenlight. A decision from the US Food and Drug Administration is expected in the next few months.
U.S. drugmaker Merck&Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.
The vaccine provided protection from Ebola virus, Sudan virus, Marburg virus and Lassa virus.
Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency
Johnson&Johnson said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck&Co Inc's vaccine.
Condition: Ebola Virus Disease Intervention: Biological: Ad26.ZEBOV, MVA-BN-Filo vaccine Sponsors: London School of Hygiene and Tropical Medicine; Epicentre; Ministère de la Santé de la RDC; Médecins Sans Frontières, France; Coalition for Epidemic Preparedness Innovations; Janssen Vaccines & Prevention B.V.; Public Health England Not yet recruiting
The government of the DRC supports use of Janssen ’s vaccine regimen as part of expanded public health response to country’s Ebola outbreak – the second-worst on record
EMA's human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ervebo (rVSVΔG-ZEBOV-GP), the first vaccine for active immunisation of individuals aged 18 years and older at risk of infection with the Ebola virus.
This article highlights the epidemiology, clinical features, diagnosis, management, and prevention of EVD. The emerging diagnostic technologies, rapid viral characterization, geospatial mapping of EVD transmission, and new treatments and vaccines are discussed.